Automotive & Transportation
Finkelstein Thompson LLP Announces Investigation of SciClone Pharmaceuticals, Inc.
WASHINGTON--([ BUSINESS WIRE ])--Finkelstein Thompson LLP announces that it is investigating potential shareholder claims concerning SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) (aSciClonea or the aCompanya).
"had received information about the Companya™s practices suggesting possible violations."
On August 9, 2010, the Company revealed that the Securities and Exchange Commission (SEC) had ainitiated a formal, non-public investigationa and issued subpoenas to SciClone regarding the Companya™s ainteractions with regulators and government-owned entities in China, activities relating to sales in China and documents relating to certain company financial and other disclosures.a The Company also revealed that it had received a letter from the Department of Justice (DOJ) regarding SciClonea™s compliance with the Foreign Corrupt Practices Act (FCPA) and that the DOJ ahad received information about the Companya™s practices suggesting possible violations.a SciClonea™s shares have fallen more than 30% since the Companya™s announcement.
If you are interested in discussing your rights as a SciClone shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at [ contact@finkelsteinthompson.com ].
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our web site at [ www.finkelsteinthompson.com ]. Attorney advertising. Prior results do not guarantee similar outcomes.